Annovis Bio, Inc. (ANVS), a clinical-stage biotechnology company, announced on Tuesday that the FDA has accepted its updated protocol for the pivotal Phase 3 Alzheimer's Disease or AD study, set to begin in January 2025.
The new protocol consolidates the original plan for two separate trials into a single 6/18-month study.
The first 6 months will focus on symptomatic effects, while the subsequent 12-month period will assess the disease-modifying potential of buntanetap.
This streamlined approach accelerates the timeline for development while ensuring scientific rigor. The 6-month symptomatic data could support a New Drug Application (NDA) filing, with the full study continuing to evaluate the long-term impact on disease progression.
Maria Maccecchini, CEO of Annovis Bio, expressed excitement over the design, saying it brings them closer to providing a novel treatment for patients with early-stage Alzheimer's disease.
Currently, ANVS is trading at $5.14 down by 5.14%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.